Rhelixa

Executive Summary

Rhelixa is a Japanese biotechnology company specializing in epigenomic analysis and multi-omics data services. As a leading epigenomics service provider, it offers next-generation sequencing, data analysis, and proprietary tools like RIAS® and Epilock® for biological age testing. The company aims to accelerate life science research and develop diagnostics and biomarkers for aging, disease risk, and mental health. Founded in 2015 and based in Tokyo, Rhelixa operates in the commercial stage with a team of 50–200 employees. Its focus on epigenomics positions it at the forefront of a rapidly growing field, with applications in aging, neurology, mental health, and infectious disease. While the company has established a solid service platform and proprietary technologies, it faces competition from global epigenomics players and must navigate regulatory hurdles for diagnostic commercialization. The increasing interest in age-related biomarkers and personalized medicine presents significant growth opportunities. Rhelixa's ability to forge strategic partnerships and expand its product pipeline will be key to capturing market share. Overall, the company has a promising foundation but requires execution on upcoming milestones to realize its potential.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation biological age test (e.g., Epilock 2.0)70% success
• Q1 2027Partnership with major pharmaceutical company for epigenetic biomarker development in aging or neurology60% success
• Q2 2027Publication of clinical validation data for mental health diagnostic biomarker55% success